N1-(2-aminophenyl)-N8-(4-(3-aminophenyl)thiazol-2-yl)octanediamide

ID: ALA4281014

PubChem CID: 145981960

Max Phase: Preclinical

Molecular Formula: C23H27N5O2S

Molecular Weight: 437.57

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  Nc1cccc(-c2csc(NC(=O)CCCCCCC(=O)Nc3ccccc3N)n2)c1

Standard InChI:  InChI=1S/C23H27N5O2S/c24-17-9-7-8-16(14-17)20-15-31-23(27-20)28-22(30)13-4-2-1-3-12-21(29)26-19-11-6-5-10-18(19)25/h5-11,14-15H,1-4,12-13,24-25H2,(H,26,29)(H,27,28,30)

Standard InChI Key:  CMFSOZAEQZHYJF-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 31 33  0  0  0  0  0  0  0  0999 V2000
   35.9029  -12.1549    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.9071  -12.9721    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   36.6085  -11.7386    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   36.6043  -10.9214    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.3116  -10.5114    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.3077   -9.6950    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.5974   -9.2892    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.8895   -9.7058    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.8968  -10.5209    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   38.0206  -10.9177    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   35.1931  -11.7458    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.4875  -12.1580    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.7777  -11.7530    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.0721  -12.1652    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.3623  -11.7603    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.3581  -10.9431    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.6484  -10.5381    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.6442   -9.7209    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   30.9427  -10.9503    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   32.3498   -9.3087    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.0982   -9.6352    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   33.6419   -9.0251    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.2297   -8.3194    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.4313   -8.4935    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   33.5582   -7.5712    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.3699   -7.4841    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.6985   -6.7367    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.2146   -6.0771    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.3984   -6.1698    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.0736   -6.9174    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.9123   -5.5129    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  1  3  1  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9  4  1  0
  5 10  1  0
  1 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 17 19  2  0
 18 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 20  2  0
 23 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 30 25  1  0
 29 31  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4281014

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 437.57

Molecular Weight (Monoisotopic): 437.1885

AlogP: 4.89

#Rotatable Bonds: 10

Polar Surface Area: 123.13

Molecular Species: NEUTRAL

HBA: 6

HBD: 4

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 7.96

CX Basic pKa: 3.80

CX LogP: 3.97

CX LogD: 3.87

Aromatic Rings: 3

Heavy Atoms: 31

QED Weighted: 0.27

Np Likeness Score: -1.35

References

1. Adhikari N, Amin SA, Trivedi P, Jha T, Ghosh B..  (2018)  HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches.,  157  [PMID:30179749] [10.1016/j.ejmech.2018.08.081]

2. Sangwan R, Rajan R, Mandal PK..  (2018)  HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.,  158  [PMID:30245394] [10.1016/j.ejmech.2018.08.073]

Source

Source(1):

• Scientific Literature